Leap therapeutics, inc. (LPTX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-31,528

-32,900

-23,424

-22,121

-21,119

-23,138

-31,211

-31,394

-30,935

-29,727

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense

45

47

49

50

49

49

50

47

35

48

0

0

0

Amortization of contract asset

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization on right-of-use asset

0

-

-

-

0

-

-

-

-

-

-

-

-

Stock-based compensation expense

3,355

3,732

3,721

3,703

3,688

3,469

3,239

2,956

2,705

5,600

0

0

0

Foreign currency loss

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of restricted stock liability

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense - related party

-

-

-

-

-

-

-

-

-

121

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-7,284

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-621

-302

-98

-282

137

297

66

535

146

99

0

0

0

Research and development incentive receivable

-632

-643

-1,132

-809

-616

-780

340

-2,181

-1,944

-1,458

0

0

0

Contract acquisition costs

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

0

-

0

0

0

-

-113

1,606

911

1,093

0

0

0

Deferred revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability

0

-

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-23,960

-26,902

-28,058

-28,553

-27,423

-26,033

-25,352

-20,257

-21,266

-22,137

0

0

0

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

64

0

0

0

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-64

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock in connection with merger with Macrocure

-

-

-

-

-

-

-

-

-

21,165

0

0

0

Proceeds from issuance of common stock

-

-

-

-

0

-

-

-

-

10,000

0

0

0

Proceeds from the issuance of common stock, net of underwriter commissions and discounts

-

-

-

-

-

15,034

0

0

0

-

-

-

-

Proceeds from notes payable - related party

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from the exercise of common stock warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of stock options

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of deferred offering costs

1,948

437

457

176

340

359

424

343

133

2,172

0

0

0

Net cash provided by financing activities

28,100

14,817

14,796

13,475

13,223

15,906

33,841

33,908

32,920

47,763

0

0

0

Effect of exchange rate changes on cash and cash equivalents

-299

-223

171

444

533

674

557

-343

-79

-618

0

0

0

Net increase in cash and cash equivalents

3,756

-12,393

-13,191

-14,734

-13,667

-9,453

9,046

13,310

11,576

24,944

0

0

0

Supplemental disclosure of non-cash financing activities:
Reclassification of 2017 warrants from liability to equity

-

-

-

-

0

-

-

-

-

-

-

-

-

Accretion of preferred stock to redemption value

-

-

-

-

-

-

-

-

-

244

0

0

0

Dividend attributable to down round feature of warrants

303

359

0

0

0

-

-

-

-

-

-

-

-

Offering costs included in accounts payable and accrued expenses

0

-

-

-

0

-

-

-

0

-

-

-

-

Right-of-use asset recorded upon adoption of ASU 2016-02

-

1,755

0

0

0

-

-

-

-

-

-

-

-

Lease liability recorded upon adoption of ASU 2016-02

-

1,720

0

0

0

-

-

-

-

-

-

-

-

Accrued rent reclassified upon adoption of ASU 2016-02

-

35

0

0

0

-

-

-

-

-

-

-

-

Conversion of Series A Convertible Preferred Stock to prefunded warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of notes payable-related party and accrued interest convertible preferred stock into common stock

-

-

-

-

-

-

-

-

-

31,145

0

0

0

Conversion of Series B Convertible Preferred Stock to common stock

0

-

-

-

-

-

-

-

-

-

0

0

0

Series A & B Convertible Preferred Stock discount - beneficial conversion feature

0

-

-

-

-

-

-

-

-

-

-

-

-

Value of net assets acquired in connection with merger with Macrocure, excluding cash

-

-

-

-

-

-

-

-

-

96

0

0

0

Series A Convertible Preferred Stock
Proceeds from the issuance of Series convertible preferred stock

0

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Series A Convertible Preferred Stock to prefunded warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

Series A & B Convertible Preferred Stock discount - beneficial conversion feature

0

-

-

-

-

-

-

-

-

-

-

-

-

Series B Convertible Preferred Stock
Proceeds from the issuance of Series convertible preferred stock

0

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Series B Convertible Preferred Stock to common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

Series A & B Convertible Preferred Stock discount - beneficial conversion feature

0

-

-

-

-

-

-

-

-

-

-

-

-